Paul Tudor Jones Heron Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $175,865 - $355,037	66,115 Added 150.24%	110,121 $465,000
Q2 2022 Aug 15, 2022	SELL	$2.3 - $6.29 $144,088 - $394,049	-62,647 Reduced 58.74%	44,006 $123,000
Q1 2022 May 16, 2022	SELL	$4.63 - $9.94 $408,463 - $876,916	-88,221 Reduced 45.27%	106,653 $610,000
Q4 2021 Feb 14, 2022	BUY	$8.35 - $12.6 $1.63 Million - $2.46 Million	194,874 New	194,874 $1.78 Million
Q2 2021 Aug 16, 2021	SELL	$13.27 - $18.48 $685,926 - $955,231	-51,690 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$14.49 - $20.72 $748,988 - $1.07 Million	51,690 New	51,690 $838,000
Q3 2020 Nov 16, 2020	SELL	$13.67 - $17.77 $1.15 Million - $1.49 Million	-84,039 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$10.89 - $21.47 $915,184 - $1.8 Million	84,039 New	84,039 $1.24 Million
Q1 2018 May 15, 2018	SELL	$18.43 - $28.8 $1.51 Million - $2.36 Million	-81,951 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$14.8 - $18.85 $907,373 - $1.16 Million	61,309 Added 297.01%	81,951 $1.48 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $302,405 - $347,817	20,642	20,642 $333,000

180

121M

80.4K

94.9K

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $133M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.